



DEPARTMENT OF HEALTH & HUMAN SERVICES

Food and Drug Administration  
Rockville MD 20857

7-17-04 JUL -1 09:34

**Date:** June 24, 2004  
**To:** Documents Management Branch  
Food and Drug Administration  
**From:** Acting Commissioner, Food and Drug Administration  
**Subject:** SEPARATION OF FUNCTIONS: Enrofloxacin for Poultry  
(Docket No. 00N-1571)


On October 31, 2000, the Food and Drug Administration (FDA) published a notice of opportunity for hearing on the proposal to withdraw the approval of the new animal drug application for use of enrofloxacin in poultry. FDA published a revised notice on January 22, 2001. Bayer Corporation requested a hearing on this matter on November 29, 2000, and on February 20, 2002, FDA published a notice of hearing. An Initial Decision was issued by Administrative Law Judge Daniel J. Davidson on March 16, 2004.

I am revising the designation of persons to serve as the principle advisors and staff to the Commissioner in this matter to reflect that the following persons shall serve:

Susan Bernard, J.D., Dr.P.H., M.P.H.  
Steven Anderson, Ph.D., M.P.P.A.  
Carl Cerniglia, Ph.D.  
LaJuana Caldwell

As set out in 21 CFR 10.55(b)(ii), all members of FDA other than representatives of the Center for Veterinary Medicine and those otherwise designated, are also available to advise the Commissioner and participate in the functions relating to the final decision.

Although FDA's regulations do not require the Commissioner to file this separation of functions designation in the docket, I am doing so as a matter of policy.

  
Lester M. Crawford, D.V.M., PH.D.

cc: HF-1  
HFV-1  
HFC-1  
GCF-1

2000N-1571

SF 7